Pharmacokinetics of cetirizine in healthy cats

Mark G. Papich Department of Molecular and Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606.

Search for other papers by Mark G. Papich in
Current site
Google Scholar
PubMed
Close
 DVM, MS
,
Elizabeth K. Schooley Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Elizabeth K. Schooley in
Current site
Google Scholar
PubMed
Close
 DVM
, and
Carol R. Reinero Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211.

Search for other papers by Carol R. Reinero in
Current site
Google Scholar
PubMed
Close
 DVM, PhD

Abstract

Objective—To develop a high-performance liquid chromatography (HPLC) assay for cetirizine in feline plasma and determine the pharmacokinetics of cetirizine in healthy cats after oral administration of a single dose (5 mg) of cetirizine dihydrochloride.

Animals—9 healthy cats.

Procedures—Heparinized blood samples were collected prior to and 0.5, 1, 2, 4, 6, 8, 10, and 24 hours after oral administration of 5 mg of cetirizine dihydrochloride to each cat (dosage range, 0.6 to 1.4 mg/kg). Plasma was harvested and analyzed by reverse-phase HPLC. Plasma concentrations of cetirizine were analyzed with a compartmental pharmacokinetic model. Protein binding was measured by ultrafiltration with a microcentrifugation system.

Results—No adverse effects were detected after drug administration in the cats. Mean ± SD terminal half-life was 10.06 ± 4.05 hours, and mean peak plasma concentration was 3.30 ± 1.55 μg/mL. Mean volume of distribution and clearance (per fraction absorbed) were 0.24 ± 0.09 L/kg and 0.30 ± 0.09 mL/kg/min, respectively. Mean plasma concentrations were approximately 2.0 μg/mL or higher for 10 hours and were maintained at > 0.72 μg/mL for 24 hours. Protein binding was approximately 88%.

Conclusions and Clinical Relevance—A single dose of cetirizine dihydrochloride (approx 1 mg/kg, which corresponded to approximately 0.87 mg of cetirizine base/kg) was administered orally to cats. It was tolerated well and maintained plasma concentrations higher than those considered effective in humans for 24 hours after dosing. The half-life of cetirizine in cats is compatible with once-daily dosing, and the extent of protein binding is high.

Abstract

Objective—To develop a high-performance liquid chromatography (HPLC) assay for cetirizine in feline plasma and determine the pharmacokinetics of cetirizine in healthy cats after oral administration of a single dose (5 mg) of cetirizine dihydrochloride.

Animals—9 healthy cats.

Procedures—Heparinized blood samples were collected prior to and 0.5, 1, 2, 4, 6, 8, 10, and 24 hours after oral administration of 5 mg of cetirizine dihydrochloride to each cat (dosage range, 0.6 to 1.4 mg/kg). Plasma was harvested and analyzed by reverse-phase HPLC. Plasma concentrations of cetirizine were analyzed with a compartmental pharmacokinetic model. Protein binding was measured by ultrafiltration with a microcentrifugation system.

Results—No adverse effects were detected after drug administration in the cats. Mean ± SD terminal half-life was 10.06 ± 4.05 hours, and mean peak plasma concentration was 3.30 ± 1.55 μg/mL. Mean volume of distribution and clearance (per fraction absorbed) were 0.24 ± 0.09 L/kg and 0.30 ± 0.09 mL/kg/min, respectively. Mean plasma concentrations were approximately 2.0 μg/mL or higher for 10 hours and were maintained at > 0.72 μg/mL for 24 hours. Protein binding was approximately 88%.

Conclusions and Clinical Relevance—A single dose of cetirizine dihydrochloride (approx 1 mg/kg, which corresponded to approximately 0.87 mg of cetirizine base/kg) was administered orally to cats. It was tolerated well and maintained plasma concentrations higher than those considered effective in humans for 24 hours after dosing. The half-life of cetirizine in cats is compatible with once-daily dosing, and the extent of protein binding is high.

Contributor Notes

Supported in part by a grant from the Phi Zeta Pi Chapter, School of Veterinary Medicine, University of Missouri.

Dr. Papich has served as a consultant for Pfizer Incorporated and has received research support from the company.

No payment or financial support was provided by the company for this study; however, Pfizer Incorporated donated the analytic reference standard.

Presented in part at the 24th Annual Forum of the American College of Veterinary Internal Medicine, Lexington, Ky, June 2006.

The authors thank Delta Dise for technical assistance.

Address correspondence to Dr. Papich.
  • 1.

    Simons FE. Advances in H1-antihistamines. N Engl J Med 2004;351:22032217.

  • 2.

    Spangler DL, Brunton S. Efficacy and central nervous system impairment of new-generation prescription antihistamines in seasonal allergic rhinitis. South Med J 2006;99:593599.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 3.

    Polli JW, Baughman TM, Humphreys JE, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. J Pharm Sci 2003;92:20822089.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    Sheffer AL, Samuels LL. Cetirizine: antiallergic therapy beyond traditional H1 antihistamines. J Allergy Clin Immunol 1990;86:10401046.

  • 5.

    Walsh GM. Anti-inflammatory properties of antihistamines: an update. Clin Exp Allergy Rev 2005;5:2125.

  • 6.

    Barnes PJ. Histamine and serotonin. Pulm Pharmacol Ther 2001;14:329339.

  • 7.

    Pitsiu M, Hussein Z, Majid O, et al. Retrospective population pharmacokinetic analysis of cetirizine in children aged 6 months to 12 years. Br J Clin Pharmacol 2004;57:402411.

    • Search Google Scholar
    • Export Citation
  • 8.

    Brik A, Tashkin DP, Gong H Jr, et al. Effect of cetirizine, a new histamine H1 antagonist, on airway dynamics and responsiveness to inhaled histamine in mild asthma. J Allergy Clin Immunol 1987;80:5156.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 9.

    Thomson L, Blaylock MG, Sexton DW, et al. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy 2002;32:11871192.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 10.

    Charlesworth E, Kagey-Sobotka A. Norman P, et al. Effect of cetirizine on mast cell mediator release and cellular traffic during the cutaneous late-phase reaction. J Allergy Clin Immunol 1989;83:908912.

    • Search Google Scholar
    • Export Citation
  • 11.

    Varney V, Gaga M, Frew AJ, et al. The effect of a single oral dose of prednisolone or cetirizine on inflammatory cells infiltrating allergen-induced cutaneous late-phase reactions in atopic subjects. Clin Exp Allergy 1992;22:4349.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 12.

    Papich M. Antihistamines: current therapeutic use. In: Bonagura J, ed. Kirk's current veterinary therapy. 13th ed. Philadelphia: WB Saunders Co, 2000;4853.

    • Search Google Scholar
    • Export Citation
  • 13.

    Kim C-K, Yeon KJ, Ban E, et al. Narrow-bore high performance liquid chromatographic method for the determination of cetirizine in human plasma using column switching. J Pharm Biomed Anal 2005;37:603609.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 14.

    Zaater MF, Tahboub YR, Najib NM. RP-LC method for the determination of cetirizine in serum. J Pharm Biomed Anal 2000;22:739744.

  • 15.

    The US Pharmacopeial Convention. USP-NF. Rockville, Md: US Pharmacopeial Convention, 2006;621.

  • 16.

    Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetics. J Pharmacokinet Biopharm 1978;6:165175.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 17.

    Benedetti MS, Plisnier M, Kaise J, et al. Absorption, distribution, metabolism and excretion of [14C]levocetirizine, the R enantiomer of cetirizine, in healthy volunteers. Eur J Clin Pharmacol 2001;57:571582.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 18.

    Wood SG, John BA, Chasseaud LF, et al. The metabolism and pharmacokinetics of 14C-cetirizine in humans. Ann Allergy 1987;59:3134.

  • 19.

    Lefebvre RA, Rosseel MT, Bernheim J. Single dose pharmacokinetics of cetirizine in young and elderly volunteers. Int J Clin Pharmacol Res 1988;8:463470.

    • Search Google Scholar
    • Export Citation
  • 20.

    Philpot EE. Safety of second generation antihistamines. Allergy Asthma Proc 2000;21:1520.

  • 21.

    Veterinary Information Network. Available at: www.vin.com. Accessed Oct 3, 2007.

  • 22.

    Portnoy JM, Dinakar C. Review of cetirizine hydrochloride for the treatment of allergic disorders. Expert Opin Pharmacother 2004;5:125135.

  • 23.

    Urien S, Tillement JP, Ganem B, et al. A pharmacokinetic-pharmacodynamic modelling of the antihistaminic (H1) effects of cetirizine. Int J Clin Pharmacol Ther 1999;37:499502.

    • Search Google Scholar
    • Export Citation
  • 24.

    Zyrtec, cetirizine dihydrochloride tablets [product label]. New York: Pfizer Inc, 1995.

Advertisement